The patented CUROLOX® Technology is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair. The core technology is the basis for all innovative credentis products.
CURODONT™ REPAIR provides dentists with a non-invasive option for natural in-depth mineralisation or Guided Enamel Regeneration (GER) which enables the regeneration of caries lesions and similar defects. Applied to an early lesion, CURODONT™ REPAIR forms a scaffold within the lesion to guide new hydroxyapatite (tooth mineral) crystals to form and grow. Ideally, the caries is stopped and the lesion will mineralise within several weeks.
CURODONT™ PROTECT uses the CUROLOX® Technology to protect the tooth surface from acid attack. CURODONT™ D’SENZ is optimised for the treatment of dentine hypersensitivity, to be used before dental hygiene treatment or in conjunction with tooth bleaching.
With its regenerative product line, credentis supports the trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions and frequent recalls by dentists and hygienists.
About credentis ag
credentis ag is headquartered in Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNF), Aargauer Forschungsfonds and CTI in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
